Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 28  |  Issue : 3  |  Page : 670-676

Interleukin 28B polymorphism as a predictor of response to interferon therapy in hepatitis C virus patients


1 Department of Microbiology and Immunology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Microbiology and Immunology, National Liver Institute, Menoufia University, Menoufia, Egypt
3 Department of Clinical Pathology, National Liver Institute, Menoufia University, Menoufia, Egypt
4 Department of Hepatology, National Liver Institute, Menoufia University, Menoufia, Egypt

Correspondence Address:
Samah Awad
National Liver Institute, Shibin Al Kom, 32513 Menoufia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.167879

Rights and Permissions

Objective The aim of the study was to assess the predictive value of interleukin 28B (IL-28B) rs12979860 polymorphism in the response to interferon (IFN)/ribavirin (RBV) therapy in hepatitis C virus (HCV) patients and the allele frequencies of this gene in HCV patients as compared with healthy controls. Background HCV infection, one of the major causes of liver disease worldwide, is highly prevalent in Egypt, with a predominance of HCV genotype 4. The standard of care for chronic HCV infection consists of treatment with pegylated interferon-a plus ribavirin (PegIFN/RBV), which is prolonged and costly and is associated with dose-limiting side effects, increasing the need for accurate prediction of treatment failure. IL-28B gene polymorphism has been shown to be related to HCV treatment response, mainly in genotype 1. Patients and methods This study included 130 HCV-positive Egyptian patients treated with IFN/RBV therapy. They were divided into three groups according to their response to therapy. Group I included 70 patients with sustained viral response (SVR). Group II included 49 patients with no response. Group III included 11 patients with relapse, and group IV included 40 healthy controls. Liver function tests, complete blood count, evaluation of viral markers, HCV-RNA by PCR, and evaluation for IL-28B single nucleotide polymorphisms for rs12979860 were performed by PCR-RFLP in all patients. Results IL-28B genotype CC was present in 34.6% of patients, whereas CT and TT genotypes were detected in 42.3 and 23.1% of patients, respectively. Seventeen (53.8%) patients achieved an SVR, whereas 60 (46.2%) did not. Of the 70 patients with an SVR, 38 had genotype CC, 25 had genotype CT, and seven had genotype TT. Patients having the CC genotype achieved significantly higher SVR rates (84.4%) compared with CT (45.5%) and TT patients (23.3%). Conclusion The IL-28B polymorphism is an independent predictor of SVR to PegIFN/RBV in Egyptian HCV-positive patients with genotype 4.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1047    
    Printed8    
    Emailed0    
    PDF Downloaded152    
    Comments [Add]    

Recommend this journal